The study concludes that for IV ketamine, lower doses within the range of 0.2 to 0.5 mg/kg are effective for treatment-resistant depression without additional benefits at higher doses.

Recent discussions have highlighted the potential of ketamine, a drug known for its anesthetic properties, as a promising treatment for mental health disorders, particularly treatment-resistant depression (TRD).

Ketamine for bipolar depression is thought to be safe as long as the patient is also on a mood stabilizer.